Multidrug resistance in the chronic lymphoproliferative disorders

Leukemia and Lymphoma

Volumn 51, Issue 10, 2010, Pages 1793-1804

  Drain, Stephen ^a,b   Catherwood, Mark A ^a,b   Alexander, H Denis ^a,b  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

ABC transporters; Chronic lymphoproliferative disorders; multidrug resistance; plasma cell myeloma

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; AMSACRINE; BREAST CANCER RESISTANCE PROTEIN; COLCHICINE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P; HYDROCORTISONE; IRINOTECAN; LUNG RESISTANCE PROTEIN; MITHRAMYCIN; MITOMYCIN C; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; PREDNISONE; PUROMYCIN; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANION TRANSPORT; CANCER RELAPSE; CHLORIDE TRANSPORT; CHOLESTEROL TRANSPORT; CHROMOSOME 13; CHROMOSOME 16P; CHROMOSOME 21; CHROMOSOME 22; CHROMOSOME 4Q; CHROMOSOME 7Q; HUMAN; IMMUNOPRECIPITATION; IRON TRANSPORT; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; WESTERN BLOTTING;

EID: 77957737414     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.500434     Document Type: Review

References (83)

1. Piddock LJ. Multidrug-resistance efflux pumps-not just for resistance. Nat Rev Microbiol 2006;4:629-636.
2. Croop JM, Guild BC, Gros P, Housman DE. Genetics of multidrug resistance: relationship of a cloned gene to the completemultidrugresistantphenotype. CancerRes 1987;47: 5982-5988.
3. Goasguen JE, Dossot JM, Fardel O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993;81:2394-2398.
4. Sonneveld P. Multidrug resistance in haematological malig-nancies. J Intern Med 2000;247:521-534.
5. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983;221:1285-1288.
6. Sanford S, Deborshi R, Schindler M. Cell biological mechan-isms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994;91:3497-3504.
7. Sanford S, Deborshi R, Schindler M. Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci USA 1994;91:1128-1132.
8. Jamroziak K, Robak T. Pharmacogenomics ofMDR1/ABCB1 gene: the influence on risk and clinical outcome ofhaemato-logical malignancies. Hematology 2004;9:91-105. (Pubitemid 38697023)
9. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
10. Pallis M, Russell N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 2000;95: 2897-2904.
11. Gollapud S, Gupta S. Anti-P-glycoprotein antibody-induced apoptosis ofactivated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival. J Clin Immunol 2001;21:420-430.
12. Procko E, O'Mara ML, Bennett WF, Tieleman DP, Gaudet R. The mechanism of ABC transporters: general lessons from structural and functional studies of an antigenic peptide transporter. FASEB J 2009;23:1287-1302.
13. Fedasenka UU, Shman TV, Savitski VP, Belevcev MV. Expression of MDR1, LRP, BCRP and bcl-2 genes at diagnosis of childhood ALL: comparison with MRD status after induction therapy. Exp Oncol 2008;30:248-252.
14. Hegedus C, Ozvegy-Laczka C, Apati A, et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacologi-cal properties. Br J Pharmacol 2009;158:1153-1164.
15. Matthews C, Catherwood MA, Larkin AM, Clynes M, Morris TC, Alexander HD. MDR-1, but not MDR-3 gene expres-sion, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. Leuk Lymphoma 2006;47:2308-2313.
16. Hoellein A, Decker T, Bogner C, et al. Expression ofmultidrug resistance-associated ABC transporters in B-CLL is independent ofZAP70 status. J Cancer Res Clin Oncol 2010;136:403-410.
17. Hitzl M, Drescher S, van der Kuip H, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56 + natural killer cells. Pharmacogenetics 2001;11:293-298.
18. Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S. Functional evaluation of ABCB1 (P-glycoprotein) poly-morphisms: high-speed screening and structure-activity relationship analyses. Drug Metab Pharmacokinet 2004; 19:1-14.
19. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994;83:2451-2458.
20. Dahan A, Sabit H, Amidon GL. Multiple efflux pumps are involved in the transepithelial transport of colchicine: com-bined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos 2009;37:2028-2036.
21. Poller B, Drewe J, Krahenbuhl S, Huwyler J, Gutmann H. Regulation ofBCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model ofthe human blood-brain barrier. Cell Mol Neurobiol 2010;30:63-70.
22. Consoli U, Santonocito A, Stagno F, et al. Multidrug resistance mechanisms in chronic lymphocytic leukaemia. Br J Haematol 2002;116:774-780.
23. Kourti M, Vavatsi N, Gombakis N, et al. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol 2007;86:166-173.
24. Guillaume N, Gouilleux-Gruart V, Claisse JF, et al. Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2007;48: 1556-1560.
25. Nuessler V, Gieseler F, Gullis E, et al. Functional P-gp expression in multiple myeloma patients at primary diagnosis and relapse or progressive disease. Leukemia 1997;11(Suppl. 5):S10-S14.
26. Hegewisch-Becker S, Hossfeld DK. The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives. Ann Hematol 1996;72:105-117.
27. Cavalcanti GB Jr, da Cunha Vasconcelos F, Pinto de Faria G, et al. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia. Cytometry B Clin Cytom 2004; 61:1-8.
28. Oude Elferink RP, Paulusma CC. Function and pathophysio-logical importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch 2007;453:601-610.
29. Grogan TM, Spier CM, Salmon SE, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with priorchemotherapy. Blood 1993;81:490-495.
30. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005;45:872-877.
31. Ohsawa M, Ikura Y, Fukushima H, et al. Immunohistochem-ical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 2005; 68:422-431.
32. Huang WT, Huang CC, Weng SW, Eng HL. Expression of the multidrug resistance protein MRP and the lung-resistance protein LRP in nasal NK/T cell lymphoma: further exploring the role of P53 and WT1 gene. Pathology 2009;41:127-132.
33. Rodriguez C, Commes T, Robert J, Rossi JF. Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-Hodgkin's lymphoma. Leuk Res 1993;17:149-156.
34. Li L, Su LP, Ma L, Zhao J, Zhu L, Zhou YA. Expression and significance of P-gp/mdr1 mRNA, MRP and LRP in non-Hodgkin's lymphoma. Zhonghua Zhong Liu Za Zhi 2009;31:199-202.
35. Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 2007;27:77-98.
36. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-1654.
37. Cheok MH, Lugthart S, Evans WE. Pharmacogenomics of acute leukemia. Annu Rev Pharmacol Toxicol 2006;46:317-353.
38. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-1302.
39. Evers R, de Haas M, Sparidans R, et al. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 2000;83:375-383.
40. Cortez MA, Scrideli CA, Yunes JA, et al. mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia: low expression levels associated with a higher risk of toxic death. Pediatr Blood Cancer 2009;53:996-1004.
41. Plasschaert SL, de Bont ES, Boezen M, et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin CancerRes 2005;11:8661-8668.
42. Izquierdo MA, Scheffer GL, Flens MJ, et al. Broad distribu-tion of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996;148:877-887.
43. Tsimberidou AM, Paterakis G, Androutsos G, et al. Evalua-tion of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resis-tance protein in patients with primary acute myelogenous leukemia. LeukRes 2002;26:143-154.
44. Filipits M, Pohl G, Stranzl T, et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998;91:1508-1513.
45. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-3464.
46. Ross DD. Novel mechanisms ofdrug resistance in leukemia. Leukemia 2000;14:467-473.
47. Sauerbrey A, Sell W, Steinbach D, Voigt A, Zintl F. Expression of the BCRP gene (ABCG2/MXRABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol 2002;118:147-150. (Pubitemid 34779530)
48. Turner JG, Gump JL, Zhang C, et al. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 2006;108:3881-3889.
49. Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, van Veen HW. Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in lactococcus lactis. J Biol Chem 2003;278:20645-20651.
50. Raaijmakers MH, de Grouw EP, Heuver LH, et al. Impaired breast cancer resistance protein mediated drug transport in plasma cells in multiple myeloma. Leuk Res 2005;29:1455-1458.
51. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell linethatexpressesP-glycoprotein. CancerRes 1986;46:5125-5130.
52. Abbaszadegan MR, Cress AE, Futscher BW, Bellamy WT, Dalton WS. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. CancerRes 1996;56:5435-5442.
53. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006;7:861-879.
54. Andreadis C, Gimotty PA, Wahl P, et al. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lympho-ma. Blood 2007;109:3409-3416.
55. Dhooge C, De Moerloose B, Laureys G, et al. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. Br J Haematol 1999;105:676-683. (Pubitemid 29277025)
56. Styczynski J, Wysocki M, Debski R, et al. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J Cancer Res Clin Oncol 2007;133:875-893.
57. Staud F, Ceckova M, Micuda S, Pavek P. Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol 2010;596:199-222.
58. Owen A, Goldring C, Morgan P, Chadwick D, Park BK, Pirmohamed M. Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol 2005;59:365-370.
59. Larsen UL, Hyldahl Olesen L, Guldborg Nyvold C, et al. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest 2007;67:123-134.
60. Xu P, Jiang ZP, Zhang BK, Tu JY, Li HD. Impact ofMDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy chinese volunteers. Pharmacology 2008;82:221-227.
61. Comets E, Verstuyft C, Lavielle M, Jaillon P, Becquemont L, Mentre F. Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters. Eur J Clin Pharmacol 2007;63:437-449.
62. Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Safranow K, Gawronska-Szklarz B. Involvement of P-glycoprotein in the release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. J Pharm Pharmacol 2005;57:1421-1425.
63. Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Kurzawski M, Gawronska-Szklarz B. Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Eur J Pharmacol 2005;528:27-36. (Pubitemid 41773648)
64. Levesque MC, O'Loughlin CW, Weinberg JB. Use ofserum-free media to minimize apoptosis of chronic lymphocytic leukemia cells during in vitro culture. Leukemia 2001; 15:1305-1307.
65. Azab AK, Azab F, Blotta S, et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 2009;114:619-629.
66. Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Gawronska-Szklarz B. Involvement ofP-gp in the process of apoptosis in peripheral blood mononuclear cells. Int Immunopharmacol 2005;5:821-828.
67. Buda G, Martino A, Maggini V, et al. MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma. Acta Haematol 2009;122:42-45.
68. Kuhne A, Sezer O, Heider U, et al. Population pharmacoki-netics of melphalan and glutathione S-transferase polymorph-isms in relation to side effects. Clin Pharmacol Ther 2008;83:749-757.
69. Wall R, McMahon G, Crown J, Clynes M, O'Connor R. Rapid and sensitive liquid chromatography-tandem mass spectrometry for the quantitation of epirubicin and identification ofmetabolites in biological samples. Talanta 2007;72: 145-154.
70. Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 2004;3:833-838.
71. Friedenberg WR, Rue M, Blood EA, et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxor-ubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 2006;106:830-838.
72. Lagas JS, Fan L, Wagenaar E, et al. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin CancerRes 2010;16:130-140.
73. Mizutani T, Masuda M, Nakai E, et al. Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab 2008;9:167-174.
74. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-3478.
75. Jamroziak K, Balcerczak E, Smolewski P, et al. MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol Rep 2006;58:720-728.
76. Buda G, Maggini V, Galimberti S, et al. MDR1 polymorph-ism influences the outcome ofmultiple myeloma patients. Br J Haematol 2007;137:454-456.
77. Schilthuizen C, Broyl A, van der Holt B, de Knegt Y, Lokhorst H, Sonneveld P. Influence ofgenetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma. Haematologica 2007;92:277-278.
78. Drain S, Catherwood MA, Orr N, et al. ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma. Leuk Lymphoma 2009;50:566-570.
79. Salama NN, Yang Z, Bui T, Ho RJ. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci 2006;95:2293-2308.
80. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A 'silent' polymorphism in the MDR1 gene changes substrate specifi-city. Science 2007;315:525-528.
81. Maggini V, Buda G, Martino A, et al. MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics 2008;18:383-389.
82. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001;42: 1007-1017. (Pubitemid 32645780)
83. Li YH, Wang YH, Li Y, Yang L. MDR1 gene polymorphisms and clinical relevance. Yi Chuan Xue Bao 2006;33:93-104.